Moleculin Biotech Reports Preliminary Composite Complete Remission Rate Of 40% In Phase 2B/3 Miracle Trial's First 30 Subjects Treated, With Annamycin In Combination With Cytarabine For Refractory To Or Relapsed Acute Myeloid Leukemia After Induct...

-7.14%

Moleculin Biotech, Inc.

MBRX

2.08

-7.14%

Preliminary blinded CR rate showed 67% improvement over historical cytarabine response
Roughly 35% of the subjects treated to date represent ventoclax regimen failures.
First 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter; treated 35 subjects to date with another 11 identified
Continued absence of cardiotoxicity and high efficacy expected to position Annamycin as a "significant advancement" in AML treatment

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.